(Q46606851)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23929217%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

title

Integration of cytogenetic and molecular alterations in risk stratification of 318 patients with de novo non-M3 acute myeloid leukemia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23929217%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23929217%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Wen-Chien Chou

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23929217%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Jih-Luh Tang

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23929217%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Yuan-Yeh Kuo

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23929217%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Ming Yao

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23929217%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Bor-Sheng Ko

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23929217%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Tien Hwei-fang

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23929217%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

author name string

C C Lin

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23929217%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

C Y Liu

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23929217%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

C Y Chen

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23929217%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Y J Lai

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23929217%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

M H Tseng

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23929217%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

C F Huang

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23929217%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Y C Chiang

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23929217%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

F Y Lee

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23929217%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

M C Lee

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23929217%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

M C Liu

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23929217%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

C W Liu

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23929217%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

L I Lin

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23929217%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

S Y Huang

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23929217%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

S C Hsu

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23929217%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

S J Wu

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23929217%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

W Tsay

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23929217%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Y C Chen

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23929217%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

publication date

9 August 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23929217%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23929217%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

volume

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23929217%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23929217%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

page(s)

50-58

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23929217%20AND%20SRC:MED&resulttype=core&format=json

The clinical significance of cytogenetic abnormalities in acute myeloid leukaemia

7 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.236

Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.236

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.236

Molecular mutations are prognostically relevant in AML with intermediate risk cytogenetics and aberrant karyotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.236

The MLL partial tandem duplication in adults aged 60 years and older with de novo cytogenetically normal acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.236

DNMT3A Mutations in Acute Myeloid Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.236

Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.236

Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.236

ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.236

RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.236

Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.236

RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.236

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.236

Prognostic relevance of integrated genetic profiling in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.236

WT1 mutation in 470 adult patients with acute myeloid leukemia: stability during disease evolution and implication of its incorporation into a survival scoring system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.236

DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.236

Characterization of acute myeloid leukemia with PTPN11 mutation: the mutation is closely associated with NPM1 mutation but inversely related to FLT3/ITD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.236

Clinical and biological implications of partial tandem duplication of the MLL gene in acute myeloid leukemia without chromosomal abnormalities at 11q23.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.236

Characterization of CEBPA mutations in acute myeloid leukemia: most patients with CEBPA mutations have biallelic mutations and show a distinct immunophenotype of the leukemic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.236

AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.236

Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.236

TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.236

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.236

Mutation in TET2 in myeloid cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.236

Recurring mutations found by sequencing an acute myeloid leukemia genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.236

IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.236

Wilms tumor 1 gene mutations are associated with a higher risk of recurrence in young adults with acute myeloid leukemia: a study from the Acute Leukemia French Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.236

Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.236

ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.236

TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.236

A novel hierarchical prognostic model of AML solely based on molecular mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.236

Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.236

Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.236

Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.236

Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem cell transplantation for acute myeloid leukemia in first or second complete remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.236

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.236

Molecular characterization of acute myeloid leukemia

21 January 2018

1 reference

12 December 2020

RUNX1 gene mutation in primary myelodysplastic syndrome--the mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome

1 reference

12 December 2020

Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity

1 reference

12 December 2020

Landscape of TET2 mutations in acute myeloid leukemia

1 reference

12 December 2020

Nucleophosmin mutations in de novo acute myeloid leukemia: the age-dependent incidences and the stability during disease evolution

1 reference

12 December 2020

Correlation of cytogenetic results with immunophenotype, genotype, clinical features, and ras mutation in acute myeloid leukemia. A study of 235 Chinese patients in Taiwan

1 reference

12 December 2020

Acquisition of JAK2, PTPN11, and RAS mutations during disease progression in primary myelodysplastic syndrome

1 reference

12 December 2020

The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties

1 reference

12 December 2020

The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia

1 reference

12 December 2020

Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study

1 reference

12 December 2020

Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations

1 reference

12 December 2020